VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.
about
Aflibercept for neovascular age-related macular degenerationAflibercept for neovascular age-related macular degenerationThe clinical utility of aflibercept for diabetic macular edemaThe role of aflibercept in the management of diabetic macular edemaOptimal combination of antiangiogenic therapy for hepatocellular carcinomaAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesExtracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.A systems biology view of blood vessel growth and remodellingDevelopment of Cell-SELEX Technology and Its Application in Cancer Diagnosis and TherapyA two-compartment model of VEGF distribution in the mouseFirst-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsThe Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial CellsLlama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral moleculesTumor angiogenesisPharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detailed Model.Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cellsDiclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activityAutologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastasesFundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesAflibercept for the treatment of age-related macular degeneration.Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor.Anti-VEGF Cancer Therapy in Nephrology PracticePhase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeysTargeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction modelZiv-aflibercept in metastatic colorectal cancerAflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma modelA pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsEffect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activationMiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1.Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.Targeted Delivery of VEGF after a Myocardial Infarction Reduces Collagen Deposition and Improves Cardiac Function.A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradationAflibercept in pediatric solid tumors: moving beyond the trap.A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report
P2860
Q24186157-7C44F348-1F64-469C-A5D1-9A833E798204Q24193255-E87EC4D2-CF2D-4D9B-ACB5-2A2675D01B20Q26783575-498E5950-E6A1-4313-AABF-AFA90D4EF9A2Q26798348-B36E6842-D30F-4CFD-80B1-A09D019F213BQ26799458-9512CCC1-3408-4B2D-9733-ABC0B52A0AA8Q26826817-25ECEE41-8F14-4931-A4B0-2607F620FF0FQ27000351-735F3C4D-4914-4E3F-A8B5-4F443BFDF9AEQ27003945-F126B545-D26A-43BC-AD99-C2ADD55084DBQ28080168-7A542250-7CF1-4A6D-AC17-4C493586B646Q28477865-8E8BD18F-1F52-47FE-917C-27BBE12399B8Q28537681-09ACDE64-219D-4830-A172-7F46BE201AA3Q28550616-454E2338-B48F-4FE5-8BB8-90D13C33A8D1Q28741431-F5660374-A6F3-45C0-A9B6-02595B320AD0Q29614938-3F502AB9-6253-40D9-82D8-084DD9CAAA75Q31037873-53A55755-3B21-4DB2-A40B-D2C357391F2CQ33627763-2C86253D-466A-4A96-BD37-A4C2071E5FD3Q33693099-47767B33-C8E4-43BA-A561-4386C46C7FFCQ33697712-4AF1040A-2C5F-4D14-99D3-591D03195D9FQ33713800-68D2177F-A95E-4B46-881F-69282D58B8B7Q33840787-EF44F330-5616-4FC2-B73A-C39CC34AED5CQ33939215-5169CE22-0A46-48A9-A1B6-2AC998AE031EQ34063852-E24930B8-2992-45B1-A9C0-93B280CE0CFDQ34152125-C8B34681-646B-4866-9580-C60EE2669ACEQ34414237-7C21CA41-848F-405F-B4BE-5AE2CB77AC84Q34557530-4BDB1F6A-691E-4671-A506-A929822222DDQ34622172-06AB9B52-EDB9-4B0F-B0C2-A523A58EFD9CQ34658579-F896AB92-8E8C-4B46-8979-2DA4399142B6Q34658699-B8BDB906-1094-453B-9733-90E5D4E6F9E0Q35018356-CD838588-7D30-4825-8700-A3139EA2B462Q35193385-62AD2BE4-CAAF-4A24-80B5-5BF9AF492B0EQ35221047-C7BC8DD7-F874-45D9-A000-90065EED6622Q35622038-16FF8F01-A8F5-48C9-A657-71BA50825F03Q35839826-4E538C6A-64C3-43B9-B018-54F2F8FD7728Q35864213-265E7EAE-0C7D-4D35-BCE3-BBD647B7A8BBQ35938926-0A7991A9-7A8B-4EC7-BE5C-FDDFFAEB4A75Q36024383-E5038361-ED8C-4D7D-9411-2BF832869AFEQ36119864-73CCD4C1-EA77-4B66-A14A-5B229DFEE8F7Q36216092-233A0CDE-14D7-47AD-9339-978ABF4E880BQ36243664-91B72AFF-77A9-4BEA-92DC-B9AD75324455Q36243701-CEAE71D7-7514-4EAA-A6BC-6F2129A28CCB
P2860
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@ast
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@en
type
label
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@ast
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@en
prefLabel
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@ast
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@en
P2093
P2860
P356
P1476
VEGF Trap complex formation me ...... ficacious angiogenic blockade.
@en
P2093
Donna Hylton
Erica A Pyles
Gavin Thurston
George D Yancopoulos
Jocelyn Holash
John S Rudge
Michelle Russell
Neil Stahl
Nicholas Papadopoulos
P2860
P304
18363-18370
P356
10.1073/PNAS.0708865104
P407
P577
2007-11-13T00:00:00Z